Skip to main content
Journal cover image

Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction.

Publication ,  Journal Article
Saldarriaga, C; Atar, D; Stebbins, A; Lewis, BS; Abidin, IZ; Blaustein, RO; Butler, J; Ezekowitz, JA; Hernandez, AF; Lam, CSP; O'Connor, CM ...
Published in: Eur J Heart Fail
May 2022

AIMS: Coronary artery disease (CAD) portends worse outcomes in heart failure (HF). We aimed to characterize patients with CAD and worsening HF with reduced ejection fraction (HFrEF) and evaluate post hoc whether vericiguat treatment effect varied according to CAD. METHODS AND RESULTS: Cox proportional hazards were generated for the primary endpoint of cardiovascular death or HF hospitalization (CVD/HFH). CAD was defined as previous myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. Of 5048 patients in VICTORIA with available data on CAD status, 2704 had CAD and were older, were more frequently male, diabetic, and had a lower glomerular filtration rate than those without CAD (all p <0.0001). Use of implantable cardioverter defibrillators and cardiac resynchronization therapy (CRT) was higher in patients with versus without CAD (33.5% vs. 21.1%; p <0.0001 and 16.3% vs. 12.8%; p = 0.0006). The primary endpoint of CVD/HFH was higher in those with versus without CAD (40.6 vs. 30.1/100 patient-years; adjusted hazard ratio [HR] 1.23; p <0.001) as was all-cause mortality (17.9% vs. 12.7%; adjusted HR 1.32; p <0.001). The primary outcome of CVD/HFH associated with vericiguat in patients with or without CAD was 38.8 versus 27.6 per 100 patient-years and for placebo was 42.6 versus 32.7 per 100 patient-years (interaction p = 0.78). CONCLUSION: In this post hoc study, CAD was associated with more CVD and HFH in patients with HFrEF and worsening HF. Vericiguat was beneficial and safe regardless of concomitant CAD.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

May 2022

Volume

24

Issue

5

Start / End Page

782 / 790

Location

England

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Stroke Volume
  • Pyrimidines
  • Male
  • Humans
  • Heterocyclic Compounds, 2-Ring
  • Heart Failure
  • Coronary Artery Disease
  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Saldarriaga, C., Atar, D., Stebbins, A., Lewis, B. S., Abidin, I. Z., Blaustein, R. O., … VICTORIA Study Group, . (2022). Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. Eur J Heart Fail, 24(5), 782–790. https://doi.org/10.1002/ejhf.2468
Saldarriaga, Clara, Dan Atar, Amanda Stebbins, Basil S. Lewis, Imran Zainal Abidin, Robert O. Blaustein, Javed Butler, et al. “Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction.Eur J Heart Fail 24, no. 5 (May 2022): 782–90. https://doi.org/10.1002/ejhf.2468.
Saldarriaga C, Atar D, Stebbins A, Lewis BS, Abidin IZ, Blaustein RO, et al. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. Eur J Heart Fail. 2022 May;24(5):782–90.
Saldarriaga, Clara, et al. “Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction.Eur J Heart Fail, vol. 24, no. 5, May 2022, pp. 782–90. Pubmed, doi:10.1002/ejhf.2468.
Saldarriaga C, Atar D, Stebbins A, Lewis BS, Abidin IZ, Blaustein RO, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, O’Connor CM, Pieske B, Ponikowski P, Roessig L, Voors AA, Anstrom KJ, Armstrong PW, VICTORIA Study Group. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. Eur J Heart Fail. 2022 May;24(5):782–790.
Journal cover image

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

May 2022

Volume

24

Issue

5

Start / End Page

782 / 790

Location

England

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Stroke Volume
  • Pyrimidines
  • Male
  • Humans
  • Heterocyclic Compounds, 2-Ring
  • Heart Failure
  • Coronary Artery Disease
  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology